Z1252
Zofenopril calcium
>98% (HPLC), powder
别名:
(4S)-1-[(2S)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-L-proline calcium salt
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H22NO4S2 · 0.5Ca
化学文摘社编号:
分子量:
448.58
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
方案
>98% (HPLC)
表单
powder
颜色
white to off-white
溶解性
DMSO: >5 mg/mL
创始人
Bristol-Myers Squibb
储存温度
2-8°C
SMILES字符串
[Ca++].C[C@H](CSC(=O)c1ccccc1)C(=O)N2C[C@H](C[C@H]2C([O-])=O)Sc3ccccc3.C[C@H](CSC(=O)c4ccccc4)C(=O)N5C[C@H](C[C@H]5C([O-])=O)Sc6ccccc6
InChI
1S/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1
InChI key
NSYUKKYYVFVMST-LETVYOFWSA-L
生化/生理作用
Zofenopril is a long-lasting, lipophilic ACE inhibitor. Zofenopril is also an inhibitor of PEPT2, the predominant peptide transporter in kidney and choroid plexus.
Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor and a PEPT2 inhibitor.
特点和优势
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
预防措施声明
危险分类
Aquatic Acute 1 - Aquatic Chronic 1
储存分类代码
13 - Non Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
Sabina Frascarelli et al.
Journal of cardiovascular pharmacology, 54(5), 456-463 (2009-09-10)
Isolated rat hearts were perfused for 120 minutes in the presence or in the absence of 10 microM zofenoprilat, the active metabolite of zofenopril. At the end of perfusion, cardiac tissue was used to assay sarcoplasmic reticulum (SR) (45)Ca uptake
Evin Bozcali et al.
Acta cardiologica, 67(1), 87-96 (2012-03-30)
The aim of this study is to compare possible protective effects of zofenopril, enalapril and valsartan against both ischaemia/reperfusion injury as well as acute doxorubicin cardiotoxicity. All three agents have never been compared in this setting before. Sixty-four male rats
Francesco Cacciatore et al.
European journal of clinical pharmacology, 67(9), 877-883 (2011-03-30)
The pathogenic role of angiotensin-converting enzyme (ACE) inhibition in hypertensive patients regarding endothelial progenitor-cell (EPC) function is still poorly understood. The aim of the study was to evaluate EPC number, function, and relationship to carotid intima media thickness (IMT) progression.
Ertuğrul Uzar et al.
Progress in neuro-psychopharmacology & biological psychiatry, 36(1), 22-28 (2011-09-06)
The aim of this experiment was to investigate whether nebivolol and zofenopril have protective effects against oxidative damage and apoptosis induced by cerebral ischemia/reperfusion (I/R). There were seven groups of rats, with each containing eight rats. The groups were: the
Giuseppe Sacco et al.
Vascular pharmacology, 50(5-6), 166-170 (2009-04-07)
The angiotensin converting enzyme inhibitor zofenopril has been shown to possess cardioprotective effects toward myocardial damage induced by chronic doxorubicin treatment in the rat. In the present study we have investigated the relationship between cardioprotection exerted by 2 angiotensin converting
商品
Discover Bioactive Small Molecules for ADME/Tox
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持